文拉法辛缓释胶囊治疗抑郁和焦虑障碍共病60例  

Venlafaxine Sustained-Release Tablets for Treating Comorbid Depression and Anxiety in 60 Cases

作　　者：王秀丽 康瑞 张中发 

机构地区：[1]河南省郑州市第八人民医院,河南郑州450006

出　　处：《中国药业》2011年第13期63-65,共3页China Pharmaceuticals

摘　　要：目的研究文拉法辛缓释胶囊治疗抑郁、焦虑障碍共病的疗效及安全性。方法将120例抑郁、焦虑障碍共病患者随机均分为文拉法辛缓释胶囊组(研究组)和选择性5-羟色胺再摄取抑制剂组(对照组),进行对照研究,疗程12周,采用汉密顿焦虑量表、汉密顿抑郁量表、药物副作用量表评定临床疗效和不良反应。结果研究组抗焦虑、抗抑郁作用均较对照组起效快(P<0.05或P<0.01),抗焦虑疗效优于对照组(P<0.05);治疗12周末两组抗抑郁疗效相当。结论文拉法辛缓释胶囊治疗抑郁、焦虑障碍共病起效快、疗效显著、安全性高、依从性好。Objective To study the efficacy and safety of Venlafaxine Sustained-Release Tablets in the treatment of comorbid depression and anxiety.Methods A hundred and tweenty cases of comorbid and anxious were randomly divided into Venlafaxine Sustained-Release Tablet group（study group） and selective serotonin reuptake inhibitors（SSRIs） group（control group）,60 cases in each group,for the comparative study with the treatment course of 12 weeks.Hamilton Anxiety scale（HAMA）,Hamilton Depression scale（HAMD） and the medicine side effect scale were used to evaluate the clinical curative effects and adverse reactions.Results The time to onset of antianxiety and antidepression in the study group were faster than those in the control group（P 0.05 or P 0.01）.The antianxiety effect in the study group was superior to that in the control group（P 0.05）.At the end of 12-week treatment,the two groups were similar in antisuppressive effects.Conclusion Venlafaxine Sustained-Release Tablets takes effect quicker with significant efficacy,higher safety and well compliance in the treatment of comorbid depression and anxiety.

关 键 词：抑郁焦虑障碍 共病 文拉法辛缓释胶囊 选择性5-羟色胺再摄取抑制剂 

分 类 号：R969.4[医药卫生—药理学] R971.43[医药卫生—药学]